IO NewsWire

May 09, 2011 07:30 ET

(NASDAQ: VTUS) Receives a Higher Price Estimate From Analysts

Note to Editor, the Following Is an Investment Opinion Issued by The IO NewsWire

NEW YORK, NY--(Marketwire - May 9, 2011) - Ventrus BioSciences (NASDAQ: VTUS) is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders.

Ventrus has multiple late-stage clinical trial data and expected patent announcements over the next year to provide additional potential upside to the share price, which has performed well since its IPO last December with a stellar gain of 220%.

Despite these impressive gains, further upside is predicted by research analysts covering the Company -- Rodman & Renshaw recently more than doubled its price target from $12 to $25 per share and predicts Ventrus could achieve a market cap in the $500 million by early 2012 if the Phase 3 clinical trial is successful.

For more information, please visit

Other active stocks are Ironwood Pharmaceuticals (NASDAQ: IRWD) Forest Laboratories (NYSE: FRX) Par Pharmaceuticals Company (NYSE: PRX)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information